2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment.

ABSTRACT:

Background

Helicobacter pylori ( H. pylori ) infection is an infectious disease with a prevalence rate of up to 50% worldwide. It can cause indigestion, gastritis, peptic ulcer, and gastric cancer. H. pylori eradication treatment can effectively control disease progression and reduce the risk of the above conditions. However, the escalating trend of antibiotic resistance presents a global challenge for H. pylori eradication. We aim to provide guidance on pharmacological treatment of H. pylori infection.

Methods

This clinical practice guideline is developed following the World Health Organization's recommended process, adopting Grading of Recommendations Assessment, Development and Evaluation in assessing evidence quality, and utilizing Evidence to Decision framework to formu

SUBMITTER: Zhou L 

PROVIDER: S-EPMC10106216 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature